Literature DB >> 8708936

Biochemical monitoring of fetal distress with serum-immunoreactive erythropoietin.

H Fahnenstich1, C Dame, A Alléra, S Kowalewski.   

Abstract

The ability of parameters like umbilical arterial pH and Apgar score to predict and/or to reflect fetal distress are limited. It is known that erythropoietin (EPO) increases when partial pressure of oxygen is insufficient for metabolic demand. Therefore we studied the levels of EPO in the cord blood of stressed neonates (n = 75). In addition, reference values for EPO were established in a group of healthy term infants (n = 54) (mean +/- SD: 20.02 +/- [mU/ml]) and in premature infants (n = 77) according to gestational age. A significant increase in EPO concentrations was found in the stressed group: 153.4 +/- 418.8 [mU/ml], p < 0.003 (n = 27) in acute stress; and 102.6 +/- 127.1 [mU/ml], p < 0.002 (n = 48) in chronic stress. However parameters like hemoglobin, hematocrit, umbilical arterial pH and Apgar-score did not correlate with EPO values. A sensitivity of 59% and a specificity of 92% was calculated. We conclude that serum EPO concentrations are capable of detecting acute and chronic stress and could be useful as a screening method. In part EPO concentrations also allow us to grade stress in pregnancies that are complicated by diseases like preeclampsia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8708936     DOI: 10.1515/jpme.1996.24.1.85

Source DB:  PubMed          Journal:  J Perinat Med        ISSN: 0300-5577            Impact factor:   1.901


  2 in total

1.  Erythropoietin concentrations and erythropoiesis in newborns suffering from renal agenesis and congenital kidney diseases.

Authors:  H Fahnenstich; C Dame
Journal:  Eur J Pediatr       Date:  1996-03       Impact factor: 3.183

Review 2.  Increased fetal plasma and amniotic fluid erythropoietin concentrations: markers of intrauterine hypoxia.

Authors:  Kari A Teramo; John A Widness
Journal:  Neonatology       Date:  2008-09-06       Impact factor: 4.035

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.